How to buy Cytokinetics Incorporated stock - 19 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cytokinetics Incorporated stock

Own Cytokinetics Incorporated stock in just a few minutes.

Cytokinetics, Incorporated is a biotechnology business based in the US. Cytokinetics Incorporated shares (CYTK) are listed on the NASDAQ and all prices are listed in US Dollars. Cytokinetics Incorporated employs 184 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Cytokinetics Incorporated

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cytokinetics Incorporated. Find the stock by name or ticker symbol: CYTK. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cytokinetics Incorporated reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cytokinetics Incorporated, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cytokinetics Incorporated. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cytokinetics Incorporated share price

Use our graph to track the performance of CYTK stocks over time.

Cytokinetics Incorporated shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$13.76 - USD$30.14
50-day moving average USD$22.42
200-day moving average USD$20.12
Wall St. target priceUSD$30.36
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.98

Buy Cytokinetics Incorporated shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cytokinetics Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cytokinetics Incorporated financials

Revenue TTM USD$55.8 million
Gross profit TTM USD$-41,123,000
Return on assets TTM -14.26%
Return on equity TTM -248.5%
Profit margin -228%
Book value $1.60
Market capitalisation USD$1.8 billion

TTM: trailing 12 months

Shorting Cytokinetics Incorporated shares

There are currently 9.0 million Cytokinetics Incorporated shares held short by investors – that's known as Cytokinetics Incorporated's "short interest". This figure is 7.7% down from 9.7 million last month.

There are a few different ways that this level of interest in shorting Cytokinetics Incorporated shares can be evaluated.

Cytokinetics Incorporated's "short interest ratio" (SIR)

Cytokinetics Incorporated's "short interest ratio" (SIR) is the quantity of Cytokinetics Incorporated shares currently shorted divided by the average quantity of Cytokinetics Incorporated shares traded daily (recently around 1.1 million). Cytokinetics Incorporated's SIR currently stands at 8.17. In other words for every 100,000 Cytokinetics Incorporated shares traded daily on the market, roughly 8170 shares are currently held short.

However Cytokinetics Incorporated's short interest can also be evaluated against the total number of Cytokinetics Incorporated shares, or, against the total number of tradable Cytokinetics Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytokinetics Incorporated's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Cytokinetics Incorporated shares in existence, roughly 130 shares are currently held short) or 0.1522% of the tradable shares (for every 100,000 tradable Cytokinetics Incorporated shares, roughly 152 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cytokinetics Incorporated.

Find out more about how you can short Cytokinetics Incorporated stock.

Cytokinetics Incorporated share dividends

We're not expecting Cytokinetics Incorporated to pay a dividend over the next 12 months.

Have Cytokinetics Incorporated's shares ever split?

Cytokinetics Incorporated's shares were split on a 1:6 basis on 24 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics Incorporated shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics Incorporated shares which in turn could have impacted Cytokinetics Incorporated's share price.

Cytokinetics Incorporated share price volatility

Over the last 12 months, Cytokinetics Incorporated's shares have ranged in value from as little as $13.76 up to $30.14. A popular way to gauge a stock's volatility is its "beta".

CYTK.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics Incorporated's is 1.3469. This would suggest that Cytokinetics Incorporated's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cytokinetics Incorporated overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site